Substance Use Disorder Diagnosis: Criteria and Clinical Process
A substance use disorder diagnosis is not a moral judgment — it is a clinical determination based on specific, measurable criteria that have been standardized across the American healthcare system. This page covers how that determination is made, what criteria clinicians use, how severity gets classified, and where the edges of the diagnosis are drawn. For anyone trying to understand what a formal assessment actually involves, the process is more structured — and more specific — than most people expect.
Definition and scope
The authoritative framework for diagnosing substance use disorder in the United States is the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), published by the American Psychiatric Association. The DSM-5 replaced two older, separate categories — substance abuse and substance dependence — with a single spectrum diagnosis, a change that took effect when the manual was released in 2013.
Under this framework, substance use disorder is defined by the presence of a cluster of cognitive, behavioral, and physiological symptoms indicating continued use of a substance despite significant substance-related problems. The diagnosis applies across 10 distinct substance classes, including alcohol, opioids, stimulants, cannabis, and sedatives. The disorder is not substance-specific at its diagnostic core — the same 11-criterion framework applies regardless of which substance is involved.
The scope of the problem is substantial. The Substance Abuse and Mental Health Services Administration (SAMHSA, 2023 National Survey on Drug Use and Health) estimated that approximately 48.7 million people in the United States met criteria for a substance use disorder in 2022 — roughly 17.3% of the population aged 12 or older.
How it works
A clinician — typically a psychiatrist, psychologist, licensed clinical social worker, or addiction medicine specialist — conducts a structured clinical interview and reviews relevant history. The DSM-5 provides 11 diagnostic criteria across four domains: impaired control, social impairment, risky use, and pharmacological criteria (tolerance and withdrawal). The number of criteria met within a 12-month period determines both the diagnosis and its severity rating.
The 11 DSM-5 criteria, organized by domain:
The severity classification is direct: 2–3 criteria indicate mild disorder, 4–5 indicate moderate, and 6 or more indicate severe. This three-tier severity scale replaced the older binary of abuse versus dependence and is clinically significant — severity rating shapes treatment recommendations, including whether residential or outpatient settings are appropriate.
Common scenarios
A primary care physician notices elevated liver enzymes in a 44-year-old patient and asks about alcohol use. The patient reports drinking nightly but denies problems. A structured screening tool — the AUDIT-C, developed by the World Health Organization, uses a 3-question format scoring 0–12 — suggests hazardous use, and the physician refers to a behavioral health specialist for a full DSM-5 assessment. This is one of the most common diagnostic pathways: incidental medical findings triggering formal evaluation.
Another common scenario involves the criminal justice system. Courts frequently mandate substance use assessments as part of diversion programs, probation conditions, or pre-sentencing evaluations. In these cases the clinician's role is independent — the diagnosis follows clinical criteria, not legal ones, though the process of accessing evaluation and treatment can look different when entry is court-ordered rather than voluntary.
A third pattern involves families seeking evaluation for a family member who does not yet recognize a problem. Here, the clinician must assess the individual directly — collateral information from family can inform history, but the diagnosis requires the patient's own reported symptoms meeting threshold criteria.
Decision boundaries
The diagnostic line matters because not all problematic substance use qualifies as a disorder. Criterion thresholds are intentional: a person who meets only one DSM-5 criterion does not receive a substance use disorder diagnosis, even if their use is concerning. Clinicians distinguish between hazardous use, harmful use, and diagnosable disorder — a distinction that affects coding, insurance coverage, and treatment access.
A complicating factor is comorbidity. The National Institute on Drug Abuse (NIDA, Comorbidity Research Overview) reports that approximately half of people with a mental health disorder will also experience a substance use disorder at some point — and the symptoms of each can obscure or mimic the other. A clinician diagnosing substance use disorder in the presence of untreated depression, PTSD, or bipolar disorder must assess whether substance use criteria are met independently of mood symptoms. This is not always clean.
Tolerance and withdrawal — criteria 10 and 11 — carry a specific caveat in the DSM-5: they do not count toward the diagnosis when they occur solely as a result of prescribed medications taken as directed. A patient on long-term opioid therapy for chronic pain who is physically dependent on their prescription does not meet those two criteria for diagnostic purposes, even though the physiology is similar. That boundary has real-world significance when evaluating patients in pain management settings.
For a broader orientation to how diagnosis connects to treatment planning, the frequently asked questions resource addresses common points of confusion about what a diagnosis does and does not determine about next steps.